Literature DB >> 24823997

[Perioperative management of anticoagulation].

R Eisele1, N Melzer, P Bramlage.   

Abstract

BACKGROUND: The aim of the perioperative management of anticoagulation in patients with long-term oral anticoagulation is to minimize bleeding complications of surgical interventions.
OBJECTIVES: We aimed to give a summary of current data and to give practical recommendations for colleagues practicing surgery.
MATERIAL AND METHODS: This article gives a narrative overview of available data from 31 publications between 2000 and 2013.
RESULTS: Every perioperative decision on whether to continue oral anticoagulation is preceded by an assessment of the risk of bleeding and embolism. In cases with a low risk of bleeding, oral anticoagulation can usually be continued. In contrast, for larger interventions with a moderate to high risk of bleeding, a discontinuation of phenprocoumon with temporary bridging is required. In this case it is common practice to discontinue phenprocoumon 7-9 days preoperatively and administer heparin mostly in the form of low molecular weight heparin (LMWH) depending on the international normalized ratio (INR). In contrast perioperative management of direct oral anticoagulants (DOAC) is discussed controversially. Based on the pharmacokinetics of the DAOC, the recommendations are to minimize the anticoagulation-free interval to 2-4 half-lives (HWZ) preoperatively (1-5 days) and early postoperative restart. In this case no bridging is necessary. On the other hand, an early interruption of DOAC 5 days prior to surgery to a minimum of 2 days postoperatively is favored by some surgeons to assure an adequate perioperative hemostasis. Depending on the risk of thromboembolism, bridging is required. These recommendations are justified by limited clinical experience and the absence of antagonism.
CONCLUSION: The perioperative management of coagulation is still a challenge. While there are consolidated decision aids for phenprocoumon, the approach under DOAC treatment is still controversial due to limited data.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24823997     DOI: 10.1007/s00104-014-2738-6

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  27 in total

1.  A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization.

Authors:  Heyder Omran; Christoph Hammerstingl; Harald Schmidt; Giso von der Recke; Wilhelm Dieter Paar; Berndt Lüderitz
Journal:  Thromb Haemost       Date:  2003-08       Impact factor: 5.249

2.  Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER study.

Authors:  Ralf Eisele; Nima Melzer; Cornelia Englert; Peter Bramlage; Michael Spannagl
Journal:  Thromb Res       Date:  2012-01-26       Impact factor: 3.944

3.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Perioperative anticoagulation in patients with chronic atrial fibrillation who are undergoing elective surgery: results of a physician survey.

Authors:  J D Douketis; M A Crowther; S S Cherian
Journal:  Can J Cardiol       Date:  2000-03       Impact factor: 5.223

5.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

6.  Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Authors:  A C Spyropoulos; A G G Turpie; A S Dunn; J Spandorfer; J Douketis; A Jacobson; F J Frost
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

Review 7.  Perioperative management of patients receiving oral anticoagulants: a systematic review.

Authors:  Andrew S Dunn; Alexander G G Turpie
Journal:  Arch Intern Med       Date:  2003-04-28

8.  Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.

Authors:  C Hammerstingl; A Schmitz; R Fimmers; H Omran
Journal:  Cardiovasc Ther       Date:  2009       Impact factor: 3.023

Review 9.  Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates.

Authors:  Deborah Siegal; Jovana Yudin; Scott Kaatz; James D Douketis; Wendy Lim; Alex C Spyropoulos
Journal:  Circulation       Date:  2012-08-21       Impact factor: 29.690

10.  [Dabigatran therapy--perioperative management and interpretation of coagulation tests].

Authors:  M Spannagl; R Bauersachs; E S Debus; M Gawaz; H Gerlach; S Haas; V Hach-Wunderle; E Lindhoff-Last; H Riess; S Schellong; H Schinzel; C Bode
Journal:  Hamostaseologie       Date:  2012       Impact factor: 1.778

View more
  3 in total

1.  [Julius Springer prize for surgery 2015 awarded].

Authors:  H Dralle; C Jurek
Journal:  Chirurg       Date:  2015-05       Impact factor: 0.955

Review 2.  [Perioperative handling of anticoagulation].

Authors:  J F Lock; J Wagner; V Luber; U A Dietz; S Lichthardt; N Matthes; K Krajinovic; C-T Germer; S Knop; A Wiegering
Journal:  Chirurg       Date:  2018-02       Impact factor: 0.955

Review 3.  Perioperative management of anticoagulant therapy.

Authors:  Johanna Wagner; Johan F Lock; Carolin Kastner; Ingo Klein; Katica Krajinovic; Stefan Löb; Christoph-Thomas Germer; Armin Wiegering
Journal:  Innov Surg Sci       Date:  2019-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.